Establish Adjuvant Hub to Enable Adjuvanted Influenza Vaccines in Under Resourced Nations | Apply Online

Opportunity Summary:

This grant opportunity, titled "Establish Adjuvant Hub to Enable Adjuvanted Influenza Vaccines in Under Resourced Nations" (Funding Opportunity Number EP IDS 14 002), was issued by the U.S. Department of Health and Human Services through the Office of the Assistant Secretary for Preparedness and Response, specifically the Biomedical Advanced Research and Development Authority (BARDA). The core purpose is to strengthen pandemic influenza preparedness by expanding access to modern vaccine technologies, especially in countries that are under resourced and often last in line during global vaccine shortages. BARDA frames this as part of its broader mission to support the advanced development and availability of medical countermeasures for chemical, biological, radiological, and nuclear threats, pandemic influenza, and emerging infectious diseases, using tools such as cooperative agreements, contracts, and partnerships across public and private sectors.

The public health problem driving the opportunity is the persistent risk that a novel influenza virus will emerge and spread globally, causing severe illness and deaths. The announcement points to real-world examples that illustrate this ongoing threat, including H5N1 avian influenza, the 2009 H1N1 pandemic strain, and H7N9 avian influenza. In a pandemic scenario, having a well-matched vaccine can substantially reduce both mortality and morbidity, but the announcement emphasizes two major bottlenecks: first, global manufacturing capacity for influenza vaccines is not sufficient to meet worldwide demand during a severe pandemic; second, many developing countries rely heavily on multinational manufacturers based in wealthier nations, which can limit timely availability and affordability when every country is competing for the same limited supply. The practical implication is that without deliberate capacity-building, under resourced nations may not be able to secure enough vaccine doses quickly enough to blunt transmission and protect high-risk populations.

The specific strategy highlighted in the title is the creation of an "adjuvant hub" to enable the use of adjuvanted influenza vaccines in under resourced nations. Adjuvants are vaccine components that can enhance immune responses, and in the context of influenza pandemics they are often associated with dose-sparing benefits, meaning the same amount of antigen can potentially vaccinate more people when paired with an effective adjuvant. By supporting an adjuvant-focused capability, BARDA is aiming to increase the practical output and impact of vaccine production, helping stretch limited supplies and making a broader, faster immunization response more feasible. The opportunity sits within BARDA's larger effort to increase global pandemic influenza vaccine production capacity and supply across both developed and developing settings to support a truly global response.

The funding mechanism is a cooperative agreement, which typically signals that the government expects substantial involvement during the period of performance, not simply a hands-off grant. The program falls under the Science and Technology and other Research and Development category and is tied to CFDA number 93.360 (BARDA Biodefense Medical Countermeasure Development). The award size ranges from a floor of $1,000,000 to a ceiling of $4,000,000, and there is no cost-sharing or matching requirement stated in the summary provided. Key dates show it was posted July 7, 2014, created July 15, 2014, with an original and current closing date of August 18, 2014, and an archive date of September 17, 2014, indicating this was a time-limited solicitation from 2014 that is now closed.

Eligibility is broad across domestic U.S. organizational types, including private and public institutions of higher education, nonprofits (both with and without 501(c)(3) status), for-profit organizations other than small businesses, and various levels of government (state, county, city or township), as well as eligible tribal governments and tribal organizations. A major constraint is that non-U.S. (foreign) entities are generally not eligible for HHS grants unless the authorizing legislation explicitly allows foreign awards or the grant is for research, and the notice flags this point directly. In other words, while the goal is to benefit under resourced nations, the eligible applicant pool is structured primarily around U.S.-based entities, with foreign eligibility limited and dependent on statutory authority and the nature of the work.

Overall, this opportunity reflects BARDA's pandemic preparedness approach: invest in enabling technologies and infrastructure that can expand vaccine availability when a novel influenza virus emerges. By focusing on an adjuvant hub, the program aims to address a key leverage point in pandemic vaccination, improving the feasibility of producing and deploying adjuvanted influenza vaccines where manufacturing and access constraints are most acute. The announcement also provides a practical contact route for access issues through the Grants.gov Contact Center, reinforcing that the solicitation was administered through standard U.S. federal grants infrastructure.

Browse more business programs for Influenza Research

Browse more opportunities from the same agency: Assistant Secretary for Preparedness and Response

Browse more opportunities from the same category: Science and Technology and other Research and Development

Next opportunity: Afghanistan Jessup Moot Court Competition

Previous opportunity: Curriculum Review and Revision Inmate Behavior Management

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for EP IDS 14 002

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (EP IDS 14 002) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "EP IDS 14 002", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.